US Bancorp’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-200
Closed -$1K 3666
2017
Q1
$1K Buy
+200
New +$1.35K ﹤0.01% 3511
2016
Q1
Sell
-1,311
Closed -$7K 3724
2015
Q4
$7K Hold
1,311
﹤0.01% 3158
2015
Q3
$11K Buy
1,311
+411
+46% +$6.96K ﹤0.01% 3069
2015
Q2
$14K Hold
900
﹤0.01% 3054
2015
Q1
$14K Buy
+900
New +$16K ﹤0.01% 3049
2014
Q4
Sell
-1,466
Closed -$15K 3665
2014
Q3
$15K Hold
1,466
﹤0.01% 2945
2014
Q2
$23K Sell
1,466
-671
-31% -$9.51K ﹤0.01% 2817
2014
Q1
$40K Buy
+2,137
New +$42.8K ﹤0.01% 2577

Other funds holding PETX

US Bancorp's PETX Position: Q2 2017 in Review

US Bancorp sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2017, closing a stake of 200 shares — an estimated $1K sold.

US Bancorp first reported a position in PETX in Q1 2014 and held it in 8 quarters. The position peaked at $40K in Q1 2014. 105 funds tracked by Wall St. Rank hold PETX as of Q2 2017.

  • US Bancorp reported no remaining Aratana Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • US Bancorp sold 200 Aratana Therapeutics, Inc. shares in Q2 2017, an estimated $1K.
  • US Bancorp first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 8 quarters.
  • US Bancorp's Aratana Therapeutics, Inc. position peaked at $40K in Q1 2014.
  • 105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2017.

Based on US Bancorp's 13F filing for Q2 2017, filed 20 Jul 2017.